Locations
Palo Alto, CA, USA · San Francisco, CA, USA
industry
Biotechnology
Size
11-50 employees
Stage
Series A
founded in
2018
Gen1e Lifesciences is a clinical-stage, multi-target company with a unique AI platform. They develop novel, next-generation, immunomodulatory therapies for rare and inflammatory diseases with no effective treatments. Gen1e is supercharging the drug development cycle by applying AI to multiple-mechanism-of-action protein targets and their natural platform capabilities—creating novel therapeutics at an unprecedented pace. Their AI platform has enabled them to develop a purpose-built therapy for ARDS to reduce its $20 billion cost on society (just in the USA). Gen1e has built a rich pipeline of 21+ novel and selective immunomodulators and has plans to accelerate 2 additional devastating diseases (beyond their lead indication) to IND in the next 12 months. Their AI platform enables tremendous pace and capital efficiency as demonstrated by their progress in approximately 2 years with seed capital—a stark contrast to the typical spend of $100 million and 7+ years exhibited in the pharmaceuticals and biotech industry. With approximately 90% of rare diseases having no therapeutic treatment at all, Gen1e is taking a giant swing that will hopefully bring life-saving therapies to the lives of patients in need. Gen1e’s team has decades of experience in drug development and machine learning, and they graduated from Y Combinator and Stanford-StartX in late 2019. Gen1e is based in Palo Alto, CA.
Something looks off?